IMMUNEX OPTIMISTIC DESPITE LOSSImmunex Corp. (NASDAQ:IMNX) reported a $9.9 million net lossfor the year ended Dec. 31, with a $10.3 million loss applicableto the company's common stock.

"Immunex is in excellent financial shape as we prepare tolaunch our first therapeutic product," said Chairman Stephan A.Duzan. Immunex is awaiting Food and Drug Administrationreview of Leukine, a white blood cell stimulant for use asadjunct therapy in cancer treatment, the company said.

Fourth quarter ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $6,590 7,423 -11Net income (loss) (7,212) (4,838) -49Net income per share (loss) (.63) (.70) +10

Year ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $34,879 28,166 +24Net income (loss) (9,887) (14,245) +31Net income per share (loss) (1.10) (1.99) +48Outstanding shares 9,377 7,747 +21

GAMMA BIOLOGICAL THIRD-QUARTER PROFITS FALL

Gamma Biologicals Inc. (ASE:GBL) of Houston said sales haveincreased since it started shipping in December monoclonal-based reagents, which were approved by the Food and DrugAdministration last November. Third-quarter results last yearincluded the sale of the company's Italian subsidiary.

Third quarter ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $3,713 4,602 -19Operating income 155 489 -68Net income (loss) 172 239 -28Net income per share (loss) .04 .05 -20Outstanding shares 4,551 4,551 n.c.

CROP GENETICS REVENUES UP, PER-SHARE LOSS DEEPENS

Crop Genetics International (NASDAQ:CROP) of Hanover, Md.,said that it paid $641,300 in preferred stock dividends in thethird quarter, reducing profits applicable to commonshareholders.

Third quarter ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $1,157 550 +110Net income (loss) (1,123) (1,253) +10Net income per share (loss) (.38) (.27) -41Outstanding shares 4,685 4,669 neg.

APPOINTMENTS AND ADVANCEMENTS

ABBOTT LABS ELECTS VP

The board of directors of Abbott Laboratories of Abbott Park,Ill., elected Ellen Molleston Walvoord corporate vice presidentof investor relations.

Walvoord, who joined Abbott as director of corporatecommunications in 1988, previously was a vice president atHill & Knowlton.

(c) 1997 American Health Consultants. All rights reserved.